# OnCo record zamtocabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zamtocabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zamtocabtagene-autoleucel" ;
  schema:name "Zamtocabtagene autoleucel"@en ;
  schema:alternateName "zamtocabtagene autoleucel (MB-CART2019.1)"@en ;
  schema:description "Zamtocabtagene autoleucel is an experimental CAR-T cell therapy from Miltenyi Biomedicine in phase 2 trials for diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma, aimed at CD19 and CD20."@en ;
  schema:url <https://onco.cc/drugs/zamtocabtagene-autoleucel/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=CART2019>, <https://www.miltenyibiomedicine.com> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "CAR-T cell therapy" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:companies <https://onco.cc/companies/miltenyi-biomedicine/> ;
  onco:trials <https://onco.cc/trials/nct04792489/>, <https://onco.cc/trials/nct07288879/>, <https://onco.cc/trials/nct04844866/>, <https://onco.cc/trials/nct06508931/> .